Last updated on November 2019

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Gu rin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder


Brief description of study

The purpose of this study is to test if an experimental drug called Durvalumab (Medi4736) given by intravenous (IV) infusion is effective in treating carcinoma in situ (CIS) of the bladder that no longer responds to Bacillus Calmette-Gurin (BCG) and to collect information on the safety of these drugs and whether they cause any side effects.

Clinical Study Identifier: NCT02901548

Find a site near you

Start Over

Mount Sinai Medical Center Miami

Miami Beach, FL United States
4.22miles
  Connect »